SOURCE: Curidium Medica PLC

October 01, 2007 02:05 ET

Curidium Medica PLC announces Directorate Change

London--(Marketwire - October 1, 2007) -

               Curidium Medica plc ("Curidium" or the "Company")

           CURIDIUM FOUNDER ASSUMES CHIEF SCIENTIFIC OFFICER POSITION

          -Increased Focus to Benefit Company's Key Scientific Assets-

London, UK, 1 October 2007, Curidium Medica plc, (LSE: CUR), the personalized medicine company focused on bringing the right drug to the right patient, today announced that the Company's founder and scientific originator, Dr. Anne Bruinvels, Ph.D., who has been Chief Executive Officer (CEO) for the past six years, will assume the position of Chief Scientific Officer (CSO) of the Company, effective today. Gosse B. Bruinsma, M.D., the Company's Executive Chairman, will assume the duties and responsibilities of the CEO. This move reflects Curidium's increased focus on the commercialization and development of its diagnostic and therapeutic product portfolio since the successful identification of PsychINDx™, the Company's diagnostic blood test that classifies patients with schizophrenia/bipolar disorder into different subgroups which may result in the improved treatment of these patients.

"There is an increasing level of interest from pharmaceutical companies to work with Curidium's PsychINDx test and its proprietary platform technology Homomatrix," stated Anne Bruinvels, Ph.D. "I am very pleased to now fully focus my efforts on directing the Company's R&D efforts, particularly, at a time when the interest in Curidium's products as well as in the area of personalized medicine as a whole is reaching new heights."

"Following Curidium's recent successful financing and the effort now placed on concerted and dedicated business development initiatives, we are poised to leverage our assets in the personalized medicine space", stated Gosse B. Bruinsma, M.D., "In an effort to remain ideally prepared for this we will continue to optimize our management structure".

For further information, please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc

Anne Bruinvels +44 (0) 20 7554 8790
Chief Scientific Officer, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics

Notes to Editors

PsychINDxTM

PsychINDx™ is Curidium's schizophrenia/bipolar disorder diagnostic blood test that classifies patients into different subgroups which are each associated with distinct underlying disease mechanisms and specific drug targets. The gene expression-based test was designed using Curidium's Homomatrix® technology.

Homomatrix®

Homomatrix® is an analysis tool that uses proprietary pattern recognition tools and sequences of mathematical algorithms together with state-of-the-art statistical methods to objectively analyze large sets of gene expression and biological data from heterogeneous populations. These analyses can potentially lead to the development of diagnostics that identify treatment-responsive patients and/or patient subgroups, signaling pathways as well as drug targets. It is anticipated that Homomatrix® could be of significant value in the drug development arena where the "most likely to respond" patients could be pre-selected to clinical trials.

Schizophrenia/Bipolar Disorder

Schizophrenia is a psychotic disorder characterized in the active phase by hallucinations, delusions, disorganized thoughts/speech, disorganized or catatonic behavior, and apathy. It is estimated that 1% of the general population suffers from schizophrenia. Bipolar affective disorder, also known as manic-depressive illness, is a mental illness involving episodes of serious mania and depression. The person's mood usually swings from overly "high" and irritable to sad and hopeless, and then back again, with periods of normal mood in between. It is estimated that 0.5% of the general population suffers from bipolar affective disorder. The global market for antipsychotics, which are used to treat schizophrenia and frequently bipolar affective disorder, was valued at $12.5 billion in 2004 and is expected to grow to $20.5 billion by 2009 (The CNS Market Outlook to 2010, Reuters Business Insights, 2005). Further information about schizophrenia and bipolar affective disorder can be found at www.schizophrenia.com or www.moodswing.org.

Curidium Medica

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

 1. Diagnostics for better identification and treatment within 
    heterogeneous
    disease populations.
 2. Improved therapies identified through novel drug targets.
 3. Personalized medicines using companion diagnostics and targeted 
    treatments.
Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website: www.curidium.com.

Curidium Medica plc (c) 2002-2007. All rights reserved.
Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.
Email: info@curidium.com 
Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791



                      This information is provided by RNS
            The company news service from the London Stock Exchange